image
Healthcare - Biotechnology - NASDAQ - US
$ 0.4635
-8.42 %
$ 24.7 M
Market Cap
-0.2
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one ALXO stock under the worst case scenario is HIDDEN Compared to the current market price of 0.464 USD, ALX Oncology Holdings Inc. is HIDDEN

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one ALXO stock under the base case scenario is HIDDEN Compared to the current market price of 0.464 USD, ALX Oncology Holdings Inc. is HIDDEN

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one ALXO stock under the best case scenario is HIDDEN Compared to the current market price of 0.464 USD, ALX Oncology Holdings Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart ALXO

image
$2.0$2.0$1.8$1.8$1.6$1.6$1.4$1.4$1.2$1.2$1.0$1.0$0.8$0.8$0.6$0.6$0.4$0.415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '25
FINANCIALS
0 REVENUE
0.00%
-142 M OPERATING INCOME
16.33%
-135 M NET INCOME
16.14%
-122 M OPERATING CASH FLOW
6.48%
86.3 M INVESTING CASH FLOW
93.15%
30.8 M FINANCING CASH FLOW
-48.02%
0 REVENUE
0.00%
-30.6 M OPERATING INCOME
6.00%
-29.2 M NET INCOME
5.03%
-32 M OPERATING CASH FLOW
-26.28%
33.2 M INVESTING CASH FLOW
29.15%
328 K FINANCING CASH FLOW
30.68%
Balance Sheet ALX Oncology Holdings Inc.
image
Current Assets 134 M
Cash & Short-Term Investments 128 M
Receivables 0
Other Current Assets 6.6 M
Non-Current Assets 13.4 M
Long-Term Investments 3.52 M
PP&E 9.63 M
Other Non-Current Assets 267 K
86.45 %4.46 %6.52 %Total Assets$147.8m
Current Liabilities 18.5 M
Accounts Payable 4.5 M
Short-Term Debt 435 K
Other Current Liabilities 13.6 M
Non-Current Liabilities 15.7 M
Long-Term Debt 0
Other Non-Current Liabilities 15.7 M
13.17 %39.72 %45.84 %Total Liabilities$34.2m
EFFICIENCY
Earnings Waterfall ALX Oncology Holdings Inc.
image
Revenue 0
Cost Of Revenue 0
Gross Profit 0
Operating Expenses 142 M
Operating Income -142 M
Other Expenses -7.62 M
Net Income -135 M
00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)(140m)(140m)(160m)(160m)000(142m)(142m)8m(135m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
-118.69% ROE
-118.69%
-91.25% ROA
-91.25%
-109.84% ROIC
-109.84%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis ALX Oncology Holdings Inc.
image
00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)(140m)(140m)20192019202020202021202120222022202320232024202420252025
Net Income -135 M
Depreciation & Amortization 872 K
Capital Expenditures -447 K
Stock-Based Compensation 27.1 M
Change in Working Capital -12.4 M
Others -11 M
Free Cash Flow -122 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets ALX Oncology Holdings Inc.
image
Wall Street analysts predict an average 1-year price target for ALXO of $15.8 , with forecasts ranging from a low of $1.5 to a high of $25 .
ALXO Lowest Price Target Wall Street Target
1.5 USD 223.62%
ALXO Average Price Target Wall Street Target
15.8 USD 3316.04%
ALXO Highest Price Target Wall Street Target
25 USD 5293.74%
Price
Max Price Target
Min Price Target
Average Price Target
25252020151510105500Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 17
6. Ownership
Insider Ownership ALX Oncology Holdings Inc.
image
Sold
0-3 MONTHS
4.64 K USD 3
3-6 MONTHS
23.3 K USD 2
6-9 MONTHS
0 USD 0
9-12 MONTHS
436 K USD 3
Bought
0 USD 0
0-3 MONTHS
46.4 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
102 K USD 1
9-12 MONTHS
7. News
ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025 SOUTH SAN FRANCISCO, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced plans to report its first quarter 2025 financial results on Thursday, May 8th, 2025, before market open. globenewswire.com - 2 weeks ago
ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma - Data to be presented at AACR 2025 Annual Meeting suggest the combination of ALX Oncology's investigational CD47-blocker, evorpacept, plus rituximab and lenalidomide (R 2 ) was well-tolerated and demonstrated promising anti-tumor activity globenewswire.com - 3 weeks ago
ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints SOUTH SAN FRANCISCO, April 25, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced topline data from its Phase 2 ASPEN-03 and ASPEN-04 clinical trials. The company's investigational CD47-blocker evorpacept, when added to Merck's (known as MSD outside of the US and Canada) anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) with or without chemotherapy, did not meet the primary endpoints in the ASPEN-03 and ASPEN-04 trials of improved objective response rates (ORR) as compared to historical controls of pembrolizumab alone and pembrolizumab with chemotherapy, respectively, as a first-line treatment in patients with advanced head and neck squamous cell carcinoma (HNSCC). The combination of evorpacept and pembrolizumab with or without chemotherapy in ASPEN-03 and ASPEN-04 demonstrated a manageable safety profile and was consistent with what has been previously reported for pembrolizumab and chemotherapy in this setting. Although the company will no longer pursue evorpacept in combination with pembrolizumab in HNSCC, multiple clinical trials of evorpacept in combination with anti-cancer antibodies will continue based on established proof-of-concept. globenewswire.com - 3 weeks ago
ALX Oncology Holdings (ALXO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now ALX Oncology Holdings (ALXO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term. zacks.com - 2 months ago
ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update – Presented positive updated data from ASPEN-06 Phase 2 trial demonstrating evorpacept generates strong response and durable clinical benefit in patients with HER2-positive gastric cancer in an oral presentation at 2025 ASCO GI globenewswire.com - 2 months ago
ALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corporate Updates at R&D Day Webcast Event Event to include updates on ongoing evorpacept clinical development program and introduction of clinical trials in breast and colorectal cancers Advancing novel EGFR-targeted antibody-drug conjugate (ADC) candidate, ALX2004, into clinical-stage development with IND submission planned for Q1 2025 Company implements strategic prioritization, resource optimizations and reductions to extend cash runway into Q4 2026 Webcast featuring company leadership and external key opinion leaders to take place today at 6:00 a.m. PT/9:00 a.m. globenewswire.com - 2 months ago
ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025 SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients' lives, today announced plans to report its fourth quarter and full year 2024 financial results on Thursday, March 6th, 2025, before market open. globenewswire.com - 2 months ago
ALX Oncology to Host Virtual R&D Day on March 5, 2025 SOUTH SAN FRANCISCO, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients' lives, today announced that it will host a virtual Research and Development (R&D) Day webcast on Wednesday, March 5, 2025, at 6:00 a.m. globenewswire.com - 3 months ago
ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer SOUTH SAN FRANCISCO, Calif., Jan. 23, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients' lives, announced positive updated data from the ASPEN-06 Phase 2 clinical trial demonstrating that the company's investigational CD47-blocker evorpacept generates a durable clinical response with a well-tolerated safety profile among patients with previously treated HER2-positive advanced gastric cancer (GC) or gastroesophageal junction (GEJ) cancer. The updated results, which build upon previously announced topline results, will be shared today in an oral presentation (Abstract #332) at the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in San Francisco. globenewswire.com - 3 months ago
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules SOUTH SAN FRANCISCO, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings, Inc. (“ALX Oncology” or the “Company”), (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients' lives, today announced that effective January 21, 2025, the Compensation Committee of the Board of Directors of ALX Oncology granted an inducement stock option to purchase a total of 600,000 shares of ALX Oncology's common stock to Harish Shantharam, the Company's Chief Financial Officer, in connection with the commencement of his employment. Mr. Shantharam's inducement stock option is subject to the terms of the ALX Oncology Holdings Inc. 2025 Inducement Equity Incentive Plan and related forms of agreements, and were granted as inducements material to Mr. Shantharam to enter into employment with ALX Oncology in accordance with Nasdaq Listing Rule 5635(c)(4). globenewswire.com - 3 months ago
ALX Oncology to Host Virtual Company Event Highlighting Updated Data from ASPEN-06 Phase 2 Trial Presented at 2025 ASCO GI SOUTH SAN FRANCISCO, Calif., Jan. 21, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients' lives, today announced that the company will host a virtual event on Thursday, January 23, at 1:00 p.m. PT/4:00 p.m. ET to discuss updated data from the ASPEN-06 Phase 2 clinical trial evaluating the company's investigational CD47-blocker evorpacept in patients with previously treated HER2-positive advanced gastric cancer (GC) or gastroesophageal junction (GEJ) cancer. globenewswire.com - 3 months ago
Is ALX Oncology Holdings (ALXO) Outperforming Other Medical Stocks This Year? Here is how ALX Oncology Holdings Inc. (ALXO) and Ginkgo Bioworks Holdings, Inc. (DNA) have performed compared to their sector so far this year. zacks.com - 4 months ago
8. Profile Summary

ALX Oncology Holdings Inc. ALXO

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 24.7 M
Dividend Yield 0.00%
Description ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California.
Contact 323 Allerton Avenue, South San Francisco, CA, 94080 https://www.alxoncology.com
IPO Date July 17, 2020
Employees 80
Officers Dr. Allison Dillon Ph.D. Chief Business Officer Ms. Shelly Pinto CPA Senior Vice President of Finance & Chief Accounting Officer Ms. Lisa Sauer Senior Vice President of Regulatory Affairs & Quality Assurance Dr. Lin Yeong-Liang M.D., M.S. Senior Vice President of Drug Safety & Pharmacovigilance Mr. Harish Shantharam C.F.A. Chief Financial Officer Dr. Athanasios Tsiatis M.D. Senior Vice President of Clinical Development Mr. Jason W. Lettmann Chief Executive Officer & Director Dr. Alan Bart Sandler M.D. Chief Medical Officer Dr. Michael Chang Ph.D. Vice President of Operations Ms. Sue Naim Senior Vice President of Clinical Operations